Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ISPI: http://www.grassrootsrd.com/Reports/infospi,_inc..pdf
The cohen price target: 1,45 $
http://www.grassrootsrd.com/Reports/infospi,_inc..pdf
The cohen price target: 1,45 $
Sorry. I noticed a news item by mistake earlier days, about the new secretary
Post Unavailable
Additional Information
Post Unavailable
Additional Information
Video of Shot in the Gas
This certificate is received in my bank branch. I am waiting to receive it. I asked yesterday and I receive the certificate soon, otherwise I will present my complaint through association of consumer protection and banking services. I think it will not tarry.
Sorry. Now I could not answer before. The certificate for SKGO costs 30 euros. That depends on the broker or bank.
ACTC NEW:
BioWorld Today
23 February 2010
By Donna Young,, Washington Editor
[What follows is the full text of the news story.]
WASHINGTON - The National Institute of Health's proposal to revise its definition of human embryonic stem cells (hESC) to permit earlier stage embryos may at first glance appear to be a minor technical change. But to firms like Advanced Cell Technology Inc., which has sunk a "fortune" into developing the cell lines, it is "hugely important," said Robert Lanza, chief scientific officer for the Worcester, Mass.-based biotech.
The NIH late Friday afternoon proposed changing the definition of hESCs issued in guidelines last July from "cells that are derived from the inner cell mass of blastocyst stage human embryos" to "pluripotent cells that are derived from early stage human embryos, up to and including the blastocyst stage." (See BioWorld Today, July 7, 2009, and Feb. 22, 2010.)
That change would allow ACT's five single-blastomere lines currently under review at the NIH to receive federal funding for research, if approved by the agency. ACT currently has an investigational new drug application (IND) under review at the FDA for a Phase I/II trial using its MA09 single-blastomere line to treat Stargardt disease, a genetic condition and the leading cause of juvenile blindness in the U.S., Lanza told BioWorld Today.
The IND currently is on hold while ACT addresses some of the FDA's questions, but Lanza said the company is hoping to initiate the study by the end of the third quarter.
The hESC definition change also would affect ACT's four other NED, or "no embryo destruction," lines awaiting placement on the NIH registry: NED1, NED2, NED3 and NED4.
ACT's approach, Lanza said, is "simply plucking one cell out of the embryo in a way that doesn't harm the embryo and then you can create a line from that cell."
The MA09 line is the one the firm has been using for its "master bank" for its clinical trials, he noted. "What we have found, interestingly, is that these lines have opportunities superior to the other embryonic stem cell lines that we have been studying," he said. ACT's five lines affected by the NIH's proposed change were generated under good manufacturing practice conditions, "so that they are suitable for use in patients," Lanza said. "It turns out that when we look at embryonic stem cells side by side, that our best performers, the cells that do some of these tricks most efficiently, actually were the single-cell derived embryos," he said. "So if we want to make various endothelial cells or vascular cells to repair damage, we find that the single blastomere lines, at least one or two of them, are five times greater in efficiently generating the cells. That is huge when you talking about having to expand cells into very large numbers for medical therapy."
Lanza insisted that "it shouldn't really matter what cells" hESC lines are derived from.
"These are coming from the spirit of the law that these are leftover embryos with the proper consent forms that were discarded from IVF clinics or from leftover embryos that were not being used," he said. "So whether or not you generate your lines from this or that cell from the embryo really shouldn't matter," Lanza said.
And because the single blastomere method does not require the destruction of the embryo, "it could be strongly argued that these lines are far more ethical," he said.
Given the "many years" of data ACT has collected, including lifetime animal studies to show the cells do not form teratomas, it would have been "a real shame" if the NIH had ignored the pleas from the company and other researchers to revise the guidelines, Lanza said.
"You can imagine changing the official guidelines is not trivial," he said. "So my hat is off to them for correcting this. They are doing the right thing here. We are very pleased that they were willing to make this correction."
Lanza noted that his firm and its collaborators have applied for several NIH grants, which currently are on hold until ACT's lines are approved.
The company's efforts in winning federal funding, he said, "got caught" in President Bush's 2001 order that restricted federal funding for hESC research, which was lifted last March by President Obama. (See BioWorld Today, March 10, 2009, and March 11, 2009.)
The firm had a solicitation at the Department of Defense for $5.6 million to create universal blood, but none of the Bush lines were O negative, and ACT was unable to get the White House to sign off on permitting the use of the company's single blastomere technique.
"They let the clock run out on it," Lanza said. If the NIH revises it guidelines and approves ACT's five single-blastomere lines, it would open the possibility that the firm could potentially get the DoD to reconsider, he added.
Meanwhile, the company is in discussions with the Foundation for Fighting Blindness for appropriated funding from DoD to back ACT's clinical trial.
"There are many, many people who could greatly benefit from this technology," Lanza said. "It would be very sad for us not to be able to move ahead and try to help as many people as possible."
ACTC NEW:
BioWorld Today
23 February 2010
By Donna Young,, Washington Editor
[What follows is the full text of the news story.]
WASHINGTON - The National Institute of Health's proposal to revise its definition of human embryonic stem cells (hESC) to permit earlier stage embryos may at first glance appear to be a minor technical change. But to firms like Advanced Cell Technology Inc., which has sunk a "fortune" into developing the cell lines, it is "hugely important," said Robert Lanza, chief scientific officer for the Worcester, Mass.-based biotech.
The NIH late Friday afternoon proposed changing the definition of hESCs issued in guidelines last July from "cells that are derived from the inner cell mass of blastocyst stage human embryos" to "pluripotent cells that are derived from early stage human embryos, up to and including the blastocyst stage." (See BioWorld Today, July 7, 2009, and Feb. 22, 2010.)
That change would allow ACT's five single-blastomere lines currently under review at the NIH to receive federal funding for research, if approved by the agency. ACT currently has an investigational new drug application (IND) under review at the FDA for a Phase I/II trial using its MA09 single-blastomere line to treat Stargardt disease, a genetic condition and the leading cause of juvenile blindness in the U.S., Lanza told BioWorld Today.
The IND currently is on hold while ACT addresses some of the FDA's questions, but Lanza said the company is hoping to initiate the study by the end of the third quarter.
The hESC definition change also would affect ACT's four other NED, or "no embryo destruction," lines awaiting placement on the NIH registry: NED1, NED2, NED3 and NED4.
ACT's approach, Lanza said, is "simply plucking one cell out of the embryo in a way that doesn't harm the embryo and then you can create a line from that cell."
The MA09 line is the one the firm has been using for its "master bank" for its clinical trials, he noted. "What we have found, interestingly, is that these lines have opportunities superior to the other embryonic stem cell lines that we have been studying," he said. ACT's five lines affected by the NIH's proposed change were generated under good manufacturing practice conditions, "so that they are suitable for use in patients," Lanza said. "It turns out that when we look at embryonic stem cells side by side, that our best performers, the cells that do some of these tricks most efficiently, actually were the single-cell derived embryos," he said. "So if we want to make various endothelial cells or vascular cells to repair damage, we find that the single blastomere lines, at least one or two of them, are five times greater in efficiently generating the cells. That is huge when you talking about having to expand cells into very large numbers for medical therapy."
Lanza insisted that "it shouldn't really matter what cells" hESC lines are derived from.
"These are coming from the spirit of the law that these are leftover embryos with the proper consent forms that were discarded from IVF clinics or from leftover embryos that were not being used," he said. "So whether or not you generate your lines from this or that cell from the embryo really shouldn't matter," Lanza said.
And because the single blastomere method does not require the destruction of the embryo, "it could be strongly argued that these lines are far more ethical," he said.
Given the "many years" of data ACT has collected, including lifetime animal studies to show the cells do not form teratomas, it would have been "a real shame" if the NIH had ignored the pleas from the company and other researchers to revise the guidelines, Lanza said.
"You can imagine changing the official guidelines is not trivial," he said. "So my hat is off to them for correcting this. They are doing the right thing here. We are very pleased that they were willing to make this correction."
Lanza noted that his firm and its collaborators have applied for several NIH grants, which currently are on hold until ACT's lines are approved.
The company's efforts in winning federal funding, he said, "got caught" in President Bush's 2001 order that restricted federal funding for hESC research, which was lifted last March by President Obama. (See BioWorld Today, March 10, 2009, and March 11, 2009.)
The firm had a solicitation at the Department of Defense for $5.6 million to create universal blood, but none of the Bush lines were O negative, and ACT was unable to get the White House to sign off on permitting the use of the company's single blastomere technique.
"They let the clock run out on it," Lanza said. If the NIH revises it guidelines and approves ACT's five single-blastomere lines, it would open the possibility that the firm could potentially get the DoD to reconsider, he added.
Meanwhile, the company is in discussions with the Foundation for Fighting Blindness for appropriated funding from DoD to back ACT's clinical trial.
"There are many, many people who could greatly benefit from this technology," Lanza said. "It would be very sad for us not to be able to move ahead and try to help as many people as possible."
ACTC; PicksThatMove.com Announces Investment Opinion on China Media Group Corp., Advanced Cell Technology Inc. and Adventrix Pharmaceuticals Inc.
CALGARY, Alberta, Feb 22, 2010 (BUSINESS WIRE) -- PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development level to bring value to shareholders. Some of our past picks had soared over 200%. To view some of our profiled stocks, please visit our website at www.picksthatmove.com.
At PicksThatMove, our team scours the technical and financials of hundreds of companies to identify those stocks showing the greatest potential for growth.
China Media Group Corp. (OTCBB: CHMD) has gotten a lot of action today. CHMD has seen its stock rise a staggering 161%, trading at 0.011, up 0.007, on volume of 13,934,748, an incredible gain for this company considering the volume at the close on Friday was 47,100.
China Media Group has a registered office in the United States with its main operations in Asia, with offices in China, Hong King, Malaysia and Australia. CHMD aims to become one of China's leading new age advertising and media companies while integrating the traditional advertising of TV, newspapers, magazines, billboards and Internet.
CHMD hit a high today of 0.035 with the day's low of 0.003, on no news. The 52 week-high for CHMD from October 2009 sits at 0.01 with the year low of 0.001 from September 2009.
Advanced Cell Technology Inc. (OTCBB: ACTC) has shaken the charts on volume today trading significantly higher then usual. ACTC is trading at 0.101, up 13.26%, reaching the day's high of 0.105 and touching down on a low of 0.096.
Advanced Cell Technology announced last week that due to its research in therapeutic cell types obtained from induced pluripotent stem cells (iPS) has been featured in several well known media outlets. The article states that iPS cells show abnormal expansion and early cellular aging, raising important questions about the future prospects for iPS cell-based therapies and supporting the use of ACT's embryo-safe single blastomere-derived human embryonic stem cell lines, which do not exhibit these problems. ACTC is a biotechnology company applying cellular technology in the field of regenerative medicine.
Adventrix Pharmaceuticals Inc. (OTCBB: ANX) has levelled off on the charts today. ANX is trading at 0.312, up 1.07%, slightly under the day's high of 0.315, touching on the day's low of 0.298, and well under the average trading volume. ANX was actively trading since the start of the year, surging in volume and reaching the 52 week-high mid January of 0.52. Back in January ANX announced that it had completed the sale of its Series E convertible preferred stock for gross proceeds of approximately $19 million.
Since its 52 week-high shares
of ANX have been bouncing from the high 0.20's to mid 30's. ANX is a pharmaceutical company whose main products are aimed to improve the performance of existing cancer treatments by focusing on their safety and use.
About Picksthatmove.com
PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies. PicksThatMove.com is not a registered investment advisor or broker-dealer. PicksThatMove.com's affiliates, offices, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value. Please follow us on Twitter and Facebook for further investment updates. We recommend you do your own Due Diligence before investing in any of the stocks mentioned above.
SOURCE: PicksThatMove.com
NEW of ACTC in pinksheets, 2-22-2010
ACTC; PicksThatMove.com Announces Investment Opinion on China Media Group Corp., Advanced Cell Technology Inc. and Adventrix Pharmaceuticals Inc.
CALGARY, Alberta, Feb 22, 2010 (BUSINESS WIRE) -- PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development level to bring value to shareholders. Some of our past picks had soared over 200%. To view some of our profiled stocks, please visit our website at www.picksthatmove.com.
At PicksThatMove, our team scours the technical and financials of hundreds of companies to identify those stocks showing the greatest potential for growth.
China Media Group Corp. (OTCBB: CHMD) has gotten a lot of action today. CHMD has seen its stock rise a staggering 161%, trading at 0.011, up 0.007, on volume of 13,934,748, an incredible gain for this company considering the volume at the close on Friday was 47,100.
China Media Group has a registered office in the United States with its main operations in Asia, with offices in China, Hong King, Malaysia and Australia. CHMD aims to become one of China's leading new age advertising and media companies while integrating the traditional advertising of TV, newspapers, magazines, billboards and Internet.
CHMD hit a high today of 0.035 with the day's low of 0.003, on no news. The 52 week-high for CHMD from October 2009 sits at 0.01 with the year low of 0.001 from September 2009.
Advanced Cell Technology Inc. (OTCBB: ACTC) has shaken the charts on volume today trading significantly higher then usual. ACTC is trading at 0.101, up 13.26%, reaching the day's high of 0.105 and touching down on a low of 0.096.
Advanced Cell Technology announced last week that due to its research in therapeutic cell types obtained from induced pluripotent stem cells (iPS) has been featured in several well known media outlets. The article states that iPS cells show abnormal expansion and early cellular aging, raising important questions about the future prospects for iPS cell-based therapies and supporting the use of ACT's embryo-safe single blastomere-derived human embryonic stem cell lines, which do not exhibit these problems. ACTC is a biotechnology company applying cellular technology in the field of regenerative medicine.
Adventrix Pharmaceuticals Inc. (OTCBB: ANX) has levelled off on the charts today. ANX is trading at 0.312, up 1.07%, slightly under the day's high of 0.315, touching on the day's low of 0.298, and well under the average trading volume. ANX was actively trading since the start of the year, surging in volume and reaching the 52 week-high mid January of 0.52. Back in January ANX announced that it had completed the sale of its Series E convertible preferred stock for gross proceeds of approximately $19 million.
Since its 52 week-high shares of ANX have been bouncing from the high 0.20's to mid 30's. ANX is a pharmaceutical company whose main products are aimed to improve the performance of existing cancer treatments by focusing on their safety and use.
About Picksthatmove.com
PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies. PicksThatMove.com is not a registered investment advisor or broker-dealer. PicksThatMove.com's affiliates, offices, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value. Please follow us on Twitter and Facebook for further investment updates. We recommend you do your own Due Diligence before investing in any of the stocks mentioned above.
SOURCE: PicksThatMove.com
CONTACT:
PicksThatMove.com Joseph Smith, 1-877-292-3917 info@picksthatmove.com http://www.picksthatmove.com
Copyright Business Wire 2010
-0-
KEYWORD: Alberta
Canada
North America
SUBJECT CODE: Investment Opinion
ACTC: PicksThatMove.com Announces Investment Opinion on China Media Group Corp., Advanced Cell Technology Inc. and Adventrix Pharmaceuticals Inc.
CALGARY, Alberta, Feb 22, 2010 (BUSINESS WIRE) -- PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development level to bring value to shareholders. Some of our past picks had soared over 200%. To view some of our profiled stocks, please visit our website at www.picksthatmove.com.
At PicksThatMove, our team scours the technical and financials of hundreds of companies to identify those stocks showing the greatest potential for growth.
China Media Group Corp. (OTCBB: CHMD) has gotten a lot of action today. CHMD has seen its stock rise a staggering 161%, trading at 0.011, up 0.007, on volume of 13,934,748, an incredible gain for this company considering the volume at the close on Friday was 47,100.
China Media Group has a registered office in the United States with its main operations in Asia, with offices in China, Hong King, Malaysia and Australia. CHMD aims to become one of China's leading new age advertising and media companies while integrating the traditional advertising of TV, newspapers, magazines, billboards and Internet.
CHMD hit a high today of 0.035 with the day's low of 0.003, on no news. The 52 week-high for CHMD from October 2009 sits at 0.01 with the year low of 0.001 from September 2009.
Advanced Cell Technology Inc. (OTCBB: ACTC) has shaken the charts on volume today trading significantly higher then usual. ACTC is trading at 0.101, up 13.26%, reaching the day's high of 0.105 and touching down on a low of 0.096.
Advanced Cell Technology announced last week that due to its research in therapeutic cell types obtained from induced pluripotent stem cells (iPS) has been featured in several well known media outlets. The article states that iPS cells show abnormal expansion and early cellular aging, raising important questions about the future prospects for iPS cell-based therapies and supporting the use of ACT's embryo-safe single blastomere-derived human embryonic stem cell lines, which do not exhibit these problems. ACTC is a biotechnology company applying cellular technology in the field of regenerative medicine.
Adventrix Pharmaceuticals Inc. (OTCBB: ANX) has levelled off on the charts today. ANX is trading at 0.312, up 1.07%, slightly under the day's high of 0.315, touching on the day's low of 0.298, and well under the average trading volume. ANX was actively trading since the start of the year, surging in volume and reaching the 52 week-high mid January of 0.52. Back in January ANX announced that it had completed the sale of its Series E convertible preferred stock for gross proceeds of approximately $19 million.
Since its 52 week-high shares of ANX have been bouncing from the high 0.20's to mid 30's. ANX is a pharmaceutical company whose main products are aimed to improve the performance of existing cancer treatments by focusing on their safety and use.
About Picksthatmove.com
PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies. PicksThatMove.com is not a registered investment advisor or broker-dealer. PicksThatMove.com's affiliates, offices, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value. Please follow us on Twitter and Facebook for further investment updates. We recommend you do your own Due Diligence before investing in any of the stocks mentioned above.
SOURCE: PicksThatMove.com
CONTACT:
PicksThatMove.com Joseph Smith, 1-877-292-3917 info@picksthatmove.com http://www.picksthatmove.com
Copyright Business Wire 2010
-0-
KEYWORD: Alberta
Canada
North America
SUBJECT CODE: Investment Opinion
Today ACTC has worked very well. Tomorrow, the better. The best news: ACTC acts discreetly, the latest come from journalistic investigations and the NIH, ie a public institution. It's the kind of news that pleased me.
ACTC Today ACTC has worked very well. Tomorrow, the better. The best news: ACTC acts discreetly, the latest come from journalistic investigations and the NIH, ie a public institution. It's the kind of news that pleased me.
All investors who, like me, have SKGO million shares. If you want to sustain and support the value of these shares, ask your agent (bank or broker) a certificate of SKGO shares you own. Ask anyone can sell the shares in your property without your permission.
I only request the certificate through my bank. I have asked the bank stating that nobody can use my stock without my permission. It costs tens of euros.
Today I have obtained the certificate of SKGO million shares I own. I encourage all investors to seek such certificates to support SKGO. I support long SKGO.
SKGO Shot in the Gas (SKGO) division agreement of terms with TV Vision
TAMPA, FL, Feb 22, 2010 /PRNewswire via COMTEX/ -- SkyBridge Technology Group, Inc. (SKGO; http://www.skybridgetechgroup.com/) Shot in the Gas (SITG) division announces agreement of terms with TV Vision. Shot in the Gas will sign a definitive marketing agreement with TV Vision Network. The agreement will call for pay on sales advertising. TV Vision will run Shot in the Gas commercials and endorsements on empty or unfulfilled slots. If a sales order is converted TV Vision will be compensated a percentage of the sale. "It's a great deal for both. We get to advertise without the upfront costs and TV Vision has opportunity for an uncapped commission." - Mike Barbee Vice President of Sales.
TV Vision Network, LLC provides programming broadcast over WTAM, a Bilingual language television station serving the Tampa Bay area with a nine-county coverage area that includes: Hillsborough, Pinellas, Pasco, Sarasota, Manatee, Citrus, Hardee, Hernando and Polk counties. WTAM can be viewed on broadcast Channel 30 throughout the Tampa Bay area and now on Verizon FiOS TV on Channel 23. The Company is headquartered in Tampa, Florida. Please visit http://www.tvvisionnetwork.tv for more information.
In other company news one of the two stainless steel merger candidates will be announced later this week on IR company web site section "CLIENT SUPPORT" TAB http://www.minamargroup.net/ or this direct link http://minamarmarketinggroup.helpserve.com/ or Pink Sheets filing service.
The company reminds our shareholders and followers to monitor PinkSheets.Com Filing Section and also our IR company web site section "CLIENT SUPPORT" TAB http://www.minamargroup.net/ or this direct link http://minamarmarketinggroup.helpserve.com/ for further updates on this and other business matters. Non-newsworthy events are not press released however posted on these two separate support sites to keep our followers advised of day-to-day events. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.
Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support Section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of SkyBridge Technology Group Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. SkyBridge Technology Group Inc. cautions you that any forward-looking information provided by or on behalf of SkyBridge Technology Group Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. SkyBridge Technology Group Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond SkyBridge Technology Group Inc.'s control. In addition to those discussed in SkyBridge Technology Group Inc.'s press releases, public filings, and statements by SkyBridge Technology Group Inc.'s management, including, but not limited to, SkyBridge Technology Group Inc.'s estimate of the sufficiency of its existing capital resources, SkyBridge Technology Group Inc.'s ability to raise additional capital to fund future operations, SkyBridge Technology Group Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match SkyBridge Technology Group Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. SkyBridge Technology Group Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, http://www.minamargroup.net (IR); For (M&A) and Corporate Matters, http://www.minamargroup.com
SOURCE SkyBridge Technology Group Inc.
www.prnewswire.com
Copyright (C) 2010 PR Newswire. All rights reserved
-0-
KEYWORD: Florida
SUBJECT CODE: CON
Shot in the Gas (SKGO) division agreement of terms with TV Vision
TAMPA, FL, Feb 22, 2010 /PRNewswire via COMTEX/ -- SkyBridge Technology Group, Inc. (SKGO; http://www.skybridgetechgroup.com/) Shot in the Gas (SITG) division announces agreement of terms with TV Vision. Shot in the Gas will sign a definitive marketing agreement with TV Vision Network. The agreement will call for pay on sales advertising. TV Vision will run Shot in the Gas commercials and endorsements on empty or unfulfilled slots. If a sales order is converted TV Vision will be compensated a percentage of the sale. "It's a great deal for both. We get to advertise without the upfront costs and TV Vision has opportunity for an uncapped commission." - Mike Barbee Vice President of Sales.
TV Vision Network, LLC provides programming broadcast over WTAM, a Bilingual language television station serving the Tampa Bay area with a nine-county coverage area that includes: Hillsborough, Pinellas, Pasco, Sarasota, Manatee, Citrus, Hardee, Hernando and Polk counties. WTAM can be viewed on broadcast Channel 30 throughout the Tampa Bay area and now on Verizon FiOS TV on Channel 23. The Company is headquartered in Tampa, Florida. Please visit http://www.tvvisionnetwork.tv for more information.
In other company news one of the two stainless steel merger candidates will be announced later this week on IR company web site section "CLIENT SUPPORT" TAB http://www.minamargroup.net/ or this direct link http://minamarmarketinggroup.helpserve.com/ or Pink Sheets filing service.
The company reminds our shareholders and followers to monitor PinkSheets.Com Filing Section and also our IR company web site section "CLIENT SUPPORT" TAB http://www.minamargroup.net/ or this direct link http://minamarmarketinggroup.helpserve.com/ for further updates on this and other business matters. Non-newsworthy events are not press released however posted on these two separate support sites to keep our followers advised of day-to-day events. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.
Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support Section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of SkyBridge Technology Group Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. SkyBridge Technology Group Inc. cautions you that any forward-looking information provided by or on behalf of SkyBridge Technology Group Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. SkyBridge Technology Group Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond SkyBridge Technology Group Inc.'s control. In addition to those discussed in SkyBridge Technology Group Inc.'s press releases, public filings, and statements by SkyBridge Technology Group Inc.'s management, including, but not limited to, SkyBridge Technology Group Inc.'s estimate of the sufficiency of its existing capital resources, SkyBridge Technology Group Inc.'s ability to raise additional capital to fund future operations, SkyBridge Technology Group Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match SkyBridge Technology Group Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. SkyBridge Technology Group Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, http://www.minamargroup.net (IR); For (M&A) and Corporate Matters, http://www.minamargroup.com
SOURCE SkyBridge Technology Group Inc.
www.prnewswire.com
Copyright (C) 2010 PR Newswire. All rights reserved
-0-
KEYWORD: Florida
SUBJECT CODE: CON
ACTC: NIH Amending Rules to Allow ACT Lines to Qualify
From worcester rob on yahoo
BioWorld Today
22 February 2010
By Donna Young,, Washington Editor
[What follows is the full text of the news story.]
WASHINGTON - The National Institutes of Friday afternoon revealed that it wants to revise its definition of human embryonic stem cells (hESCs) for purposes of federal funding.
The change could have a major impact on Worcester, Mass.-based Advanced Cell Technology, which is trying to get into the clinic with several embryonic stem cell-derived cell types. (See BioWorld Today, Feb. 12, 2010.)
The NIH said in a notice posted to its website Friday that the current definition had the "unintended consequence" of excluding hESCs from an embryo that fails to develop to the blastocyst stage.
The agency is therefore seeking to change its definition to stating that hESCs are "pluripotent cells that are derived from early stage human embryos, up to and including the blastocyst stage, are capable of dividing without differentiating for a prolonged period in culture, and are known to develop into cells and tissues of the three primary germ layers."
The proposed change in no way alters the rigorous ethical standards set forth in the NIH's guidelines, said Lana Skirboll, director of policy at the agency. The change would provide the possibility for more lines to be eligible for the federal funding, she told BioWorld Today.
"Right now we only know of eight additional lines, but there may be other lines out there that may have otherwise been excluded if we don't make this change," Skirboll said.
Five of those lines belong to Advanced Cell Technologies, which are currently under review at the NIH, and the other three lines, from George Daley at Children's Corp. and Harvard University, have been approved but have been placed on hold until the guidelines are officially changed, she noted.
The public has 30 days to comment on the NIH's proposed guidelines change.
ACTC: NIH Amending Rules to Allow ACT Lines to Qualify
From worcester rob on yahoo
BioWorld Today
22 February 2010
By Donna Young,, Washington Editor
[What follows is the full text of the news story.]
WASHINGTON - The National Institutes of Friday afternoon revealed that it wants to revise its definition of human embryonic stem cells (hESCs) for purposes of federal funding.
The change could have a major impact on Worcester, Mass.-based Advanced Cell Technology, which is trying to get into the clinic with several embryonic stem cell-derived cell types. (See BioWorld Today, Feb. 12, 2010.)
The NIH said in a notice posted to its website Friday that the current definition had the "unintended consequence" of excluding hESCs from an embryo that fails to develop to the blastocyst stage.
The agency is therefore seeking to change its definition to stating that hESCs are "pluripotent cells that are derived from early stage human embryos, up to and including the blastocyst stage, are capable of dividing without differentiating for a prolonged period in culture, and are known to develop into cells and tissues of the three primary germ layers."
The proposed change in no way alters the rigorous ethical standards set forth in the NIH's guidelines, said Lana Skirboll, director of policy at the agency. The change would provide the possibility for more lines to be eligible for the federal funding, she told BioWorld Today.
"Right now we only know of eight additional lines, but there may be other lines out there that may have otherwise been excluded if we don't make this change," Skirboll said.
Five of those lines belong to Advanced Cell Technologies, which are currently under review at the NIH, and the other three lines, from George Daley at Children's Corp. and Harvard University, have been approved but have been placed on hold until the guidelines are officially changed, she noted.
The public has 30 days to comment on the NIH's proposed guidelines change.
Advanced Cell Technology's Research Featured in Scientific American, USA Today and Newsweek
WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology announced today that its research involving therapeutic cell types obtained from induced pluripotent stem (iPS) cells has been featured in several leading news media outlets: Scientific American, USA Today and Newsweek.
The coverage highlights a recent paper in the journal Stem Cells co-authored by ACT lead by its Chief Scientific Officer, Dr. Robert Lanza MD, and its collaborators. The paper reports that iPS cells exhibit abnormal expansion and early cellular aging, raising important questions about the future prospects for iPS cell-based therapies and supporting the use of ACT's embryo-safe single blastomere-derived human embryonic stem cell lines, which do not exhibit these problems.
The Scientific American article, "Cell-Off: Induced Pluripotent Stem Cells Fall Short of Potential Found in Embryonic Version" includes the following passage: "The act of reprogramming cells to make them as capable as ones from embryos apparently can result in aberrant cells that age and die abnormally, suggesting there is a long way to go to prove such cells are really like embryonic stem cells and can find use in therapies." The story is available at: http://www.scientificamerican.com/article.cfm?id=cell-induced-pluripotent#comments
The USA Today article is headlined, "Stem Cell Articles Show Early Aging Abnormalities." In the story, Maria Blasco, of the Spanish National Cancer Center of Madrid, who was not part of the study, is quoted as saying, "the authors [of the article] show that induced stem cells are not of the same 'quality' as embryonic stem cells, and that induced-derived cell types tend to age and die earlier than those derived from embryonic stem cells."
It is available at: http://content.usatoday.com/communities/sciencefair/post/2010/02/stem-cell-alternatives-show-early-aging-abnormalities/1
The Newsweek story, "Still No Truce in the Stem Cell Wars," discusses the "bad news" heralded by ACT's study for theoretical uses for iPS cells with stem cells produced by adults. ACT's technology platform uses embryonic stem cells. The article is available at: http://www.newsweek.com/id/233454.
"This study, published in Stem Cells, highlights the challenges often faced in attempting to translate promising science into clinical results," said William M. Caldwell, IV, Chairman and CEO of Advanced Cell. "We are currently working on a solution to the problems raised by this research, and hope to be able to provide details shortly. We believe this study further validates the need to commercialize our blastomere technology, which is still on schedule to begin clinical trials in humans during the 2010 third quarter."
ACT's collaborators on the study published in Stem Cells were McLean Hospital/Harvard Medical School, the University of Illinois at Chicago, and Stem Cell & Regenerative Medicine International (SCRMI), a joint venture between ACT and Korean biotech firm CHA.
New York Times reported good news on ACTC, February 19, 2010
The National Institutes of Health is proposing to expand its definition of human embryonic stem cells, enabling the university researchers it finances to work with cells derived from a very early human egg
ACTC in New York Times:
Agency Proposes U.S.-Paid Research on Stem Cells
By NICHOLAS WADE
Published: February 19, 2010
The National Institutes of Health is proposing to expand its definition of human embryonic stem cells, enabling the university researchers it finances to work with cells derived from a very early human egg.
Skip to next paragraph
Related
Times Topics: Stem CellsThe proposal will benefit several academic researchers and a company, Advanced Cell Technology, that has filed a request with the Food and Drug Administration to test a treatment for macular degeneration, an eye disease. If approved, it would be among the first clinical tests of embryonic stem cells, which were first discovered in 1998.
Most human embryonic stem cell lines are generated from the blastocyst, an embryonic stage reached five days after fertilization. Government-financed researchers are forbidden by Congress to generate such cell lines because the blastocyst is destroyed, but were allowed by President George W. Bush to work on lines already in existence as of Aug. 9, 2001.
Researchers chafed under these limits because they could derive new lines only with private money. In December, President Obama said federally supported researchers could use many of these privately derived cell lines in their research.
The N.I.H. now proposes to add to its list of approved cell lines those created from blastomeres, the cells generated after the fertilized egg’s first few divisions.
“We thought it made no sense to exclude these,” said Lana R. Skirboll, an adviser to the director of the agency.
Dr. Robert Lanza, chief scientific officer of Advanced Cell Technology, said the company hopes to start clinical trials this year in which blastomere-derived cells will be used to treat macular degeneration. The company is now responding to F.D.A. requests for further safety data.
As a private company, Advanced Cell itself is not bound by N.I.H. rules, but its clinical trial, to be conducted with the Foundation Fighting Blindness, will be supported by the Department of Defense, so the institutes’ approval of the cells is required, Dr. Lanza said.
Researchers at Advanced Cell pioneered the development of embryonic stem cells from blastomeres and have learned how to convert these cells into the special cells that form the basement of the retina. In animal tests, the blastomere-derived retinal cells grew well and allowed the light-detecting rod and cone cells to regenerate, improving the animals’ vision, Dr. Lanza said.
Another company, Geron, has received F.D.A. approval for a clinical trial to test human embryonic stem cells to treat spinal cord injury but the trial has been postponed.
Thank you very much, Chris21. It's nice for me to read a post written in Spanish, I appreciate the care you took with me. By the way, everything I've read written by you, you still relies on SKGO. Am I wrong?
Muchas gracias, Chris21. Es agradable para mí leer un post escrito en español, valoro su atención conmigo. Por cierto, por todo lo que he leído escrito por usted, usted sigue confiando en SKGO, ¿ me equivoco?
Does anyone know when will the 8-K SKGO?. I think this is the most important thing right now.
Thank you. He has taught me something new. Now I need to know what I should order a physical certificate of the shares.
Hello. I am Spanish. I have millions of shares SKGO. I'm going to be a shareholder of SKGO over a long period of time. Now I'm reading comments on stock certificates. If it's good for SKGO, I will do everything necessary ... Please, I thank you for clarification: Should I ask my Brocker physical certificate of millions of shares I own?. Why it's good for me to ask that SKGO physical certificate?. If I explained why I will do that immediately. I pray that you forgive, but I have time off, because I'm in SKGO for a very long time.
I notice that my message is in reply to Marine. Obviously, this is because I do not know an alternative way of posting messages that are not mirror anyone.
ACTC Collection of latest news on ACTC
It is a clear recognition of scientific leadership of R. Lanza and ACTC
http://www.opednews.com/articles/Advanced-Cell-Technology-s-by-Advanced-Cell-Tech-100216-640.html
http://www.nytimes.com/2010/02/20/health/policy/20nih.html
http://www.reuters.com/article/idCNN1919518220100219?rpc=44
http://news.sciencemag.org/scienceinsider/2010/02/nih-expands-definition-of-human-.html
ACTC WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology announced today that its research involving therapeutic cell types obtained from induced pluripotent stem (iPS) cells has been featured in several leading news media outlets: Scientific American, USA Today and Newsweek.
The coverage highlights a recent paper in the journal Stem Cells co-authored by ACT lead by its Chief Scientific Officer, Dr. Robert Lanza MD, and its collaborators. The paper reports that iPS cells exhibit abnormal expansion and early cellular aging, raising important questions about the future prospects for iPS cell-based therapies and supporting the use of ACT's embryo-safe single blastomere-derived human embryonic stem cell lines, which do not exhibit these problems.
The Scientific American article, "Cell-Off: Induced Pluripotent Stem Cells Fall Short of Potential Found in Embryonic Version" includes the following passage: "The act of reprogramming cells to make them as capable as ones from embryos apparently can result in aberrant cells that age and die abnormally, suggesting there is a long way to go to prove such cells are really like embryonic stem cells and can find use in therapies." The story is available at: http://www.scientificamerican.com/article.cfm?id=cell-induced-pluripotent#comments
The USA Today article is headlined, "Stem Cell Articles Show Early Aging Abnormalities." In the story, Maria Blasco, of the Spanish National Cancer Center of Madrid, who was not part of the study, is quoted as saying, "the authors [of the article] show that induced stem cells are not of the same 'quality' as embryonic stem cells, and that induced-derived cell types tend to age and die earlier than those derived from embryonic stem cells."
It is available at: http://content.usatoday.com/communities/sciencefair/post/2010/02/stem-cell-alternatives-show-early-aging-abnormalities/1
The Newsweek story, "Still No Truce in the Stem Cell Wars," discusses the "bad news" heralded by ACT's study for theoretical uses for iPS cells with stem cells produced by adults. ACT's technology platform uses embryonic stem cells. The article is available at: http://www.newsweek.com/id/233454.
"This study, published in Stem Cells, highlights the challenges often faced in attempting to translate promising science into clinical results," said William M. Caldwell, IV, Chairman and CEO of Advanced Cell. "We are currently working on a solution to the problems raised by this research, and hope to be able to provide details shortly. We believe this study further validates the need to commercialize our blastomere technology, which is still on schedule to begin clinical trials in humans during the 2010 third quarter."
ACT's collaborators on the study published in Stem Cells were McLean Hospital/Harvard Medical School, the University of Illinois at Chicago, and Stem Cell & Regenerative Medicine International (SCRMI), a joint venture between ACT and Korean biotech firm CHA.
ACTC http://www.opednews.com/articles/Advanced-Cell-Technology-s-by-Advanced-Cell-Tech-100216-640.html
WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology announced today that its research involving therapeutic cell types obtained from induced pluripotent stem (iPS) cells has been featured in several leading news media outlets: Scientific American, USA Today and Newsweek.
The coverage highlights a recent paper in the journal Stem Cells co-authored by ACT lead by its Chief Scientific Officer, Dr. Robert Lanza MD, and its collaborators. The paper reports that iPS cells exhibit abnormal expansion and early cellular aging, raising important questions about the future prospects for iPS cell-based therapies and supporting the use of ACT's embryo-safe single blastomere-derived human embryonic stem cell lines, which do not exhibit these problems.
The Scientific American article, "Cell-Off: Induced Pluripotent Stem Cells Fall Short of Potential Found in Embryonic Version" includes the following passage: "The act of reprogramming cells to make them as capable as ones from embryos apparently can result in aberrant cells that age and die abnormally, suggesting there is a long way to go to prove such cells are really like embryonic stem cells and can find use in therapies." The story is available at: http://www.scientificamerican.com/article.cfm?id=cell-induced-pluripotent#comments
The USA Today article is headlined, "Stem Cell Articles Show Early Aging Abnormalities." In the story, Maria Blasco, of the Spanish National Cancer Center of Madrid, who was not part of the study, is quoted as saying, "the authors [of the article] show that induced stem cells are not of the same 'quality' as embryonic stem cells, and that induced-derived cell types tend to age and die earlier than those derived from embryonic stem cells."
It is available at: http://content.usatoday.com/communities/sciencefair/post/2010/02/stem-cell-alternatives-show-early-aging-abnormalities/1
The Newsweek story, "Still No Truce in the Stem Cell Wars," discusses the "bad news" heralded by ACT's study for theoretical uses for iPS cells with stem cells produced by adults. ACT's technology platform uses embryonic stem cells. The article is available at: http://www.newsweek.com/id/233454.
"This study, published in Stem Cells, highlights the challenges often faced in attempting to translate promising science into clinical results," said William M. Caldwell, IV, Chairman and CEO of Advanced Cell. "We are currently working on a solution to the problems raised by this research, and hope to be able to provide details shortly. We believe this study further validates the need to commercialize our blastomere technology, which is still on schedule to begin clinical trials in humans during the 2010 third quarter."
ACT's collaborators on the study published in Stem Cells were McLean Hospital/Harvard Medical School, the University of Illinois at Chicago, and Stem Cell & Regenerative Medicine International (SCRMI), a joint venture between ACT and Korean biotech firm CHA.